Imextor 1000mg Tablet contains Imeglimin, a novel oral antihyperglycemic agent indicated for the management of type 2 diabetes mellitus. Imeglimin acts through a unique dual mechanism by enhancing mitochondrial function and improving insulin sensitivity in peripheral tissues, thereby reducing hepatic glucose production and increasing glucose uptake. This multifaceted approach helps in achieving better glycemic control without causing significant hypoglycemia. Imextor is typically prescribed as monotherapy or as an adjunct to other antidiabetic agents, including metformin, sulfonylureas, or insulin, depending on the patient’s glycemic status and treatment goals. Clinical studies have demonstrated that Imeglimin effectively lowers HbA1c and fasting plasma glucose levels with a favorable safety profile. The recommended dosage is one 1000mg tablet taken orally once or twice daily, with or without food, as directed by a healthcare professional. Common adverse effects are generally mild and may include gastrointestinal symptoms such as nausea or diarrhea. Imextor should be used cautiously in patients with renal impairment, and regular monitoring of renal function is advised. It is contraindicated in patients with known hypersensitivity to Imeglimin or any tablet excipients. Healthcare providers should evaluate individual patient factors before initiating therapy.